Liability of the Voltage-Gated Sodium Channel Gene SCN2A R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy
Liability of the Voltage-Gated Sodium Channel Gene SCN2A R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy
复制标题
DOI：
10.1159/000236049
复制
发表时间：
2009-01-01
期刊：
影响因子：
3.5
通讯作者：
Kalofonos, Haralabos P.
中科院分区：
文献类型：
--
作者：
Argyriou, Andreas A.;Antonacopoulou, Anna G.;Kalofonos, Haralabos P.
目的：验证电压门控钠通道基因SCN2AR19K多态性与奥沙利铂诱导的周围神经病易感性的假设。方法：采用等位基因特异性引物和SYBR Green实时定量聚合酶链式反应技术，对62例晚期结直肠癌患者进行基因分型。所有患者均接受了以奥沙利铂为基础的辅助化疗。OXLIPN的严重程度由临床总神经病变评分来定义。停止治疗后，36/62例(58.1%)发展为OXLIPN。I级神经毒性14例(38.9%)，II级神经毒性22例(61.1%)。结果：26例无OXLIPN患者中，G纯合子占80.8%(n=21)，AG杂合子占19.2%(n=5)，A杂合子无一例。同样，在经历OXLIPN的患者中，I级神经毒性患者和II级神经毒性患者之间的R19K基因型没有显著差异。结论：我们的研究未能提供证据支持SCN2AR19K多态与OXLIPN之间的因果关系。版权所有(C)2009 S.Karger AG，巴塞尔
Aim: It was the aim of this study to test the hypothesis that the voltage-gated sodium channel gene SCN2A R19K polymorphism confers liability to oxaliplatin-induced peripheral neuropathy (OXLIPN). Methods: Sixty-two patients with advanced colorectal cancer were genotyped, using allele-specific primers and SYBR green in real-time polymerase chain reaction. All patients had received adjuvant oxalipla-tin-based chemotherapy. The severity of OXLIPN was defined by means of the clinical total neuropathy score. Following the discontinuation of treatment, 36/62 patients (58.1%) developed OXLIPN. Grade I neurotoxicity was revealed in 14 (38.9%) patients and grade II neurotoxicity in 22 (61.1%) patients. Results: From patients without OXLIPN (n = 26), 80.8% (n = 21) were homozygous for G, 19.2% (n = 5) were heterozygous (AG) and none was homozygous for A. The corresponding percentages for patients developing any grade of OXLIPN (n = 36) were similar. Likewise, among patients experiencing OXLIPN, insignificant differences in R19K genotypes were revealed between those with grade I versus grade II neurotoxicity. Conclusion: Our study failed to provide evidence to support a causal relationship between the SCN2A R19K polymorphism and OXLIPN. Copyright (C) 2009 S. Karger AG, Basel